DL-3-n-butylphthalide improves cerebral hypoperfusion in patients with large cerebral artherosclerotic stenosis. A single-center, randomized, double-blind, placebo-controlled study.

doi:10.21203/rs.2.23503/v1

Background: DL-3-n-butylphthalide (NBP) was demonstrated to increase the cerebral blood flow (CBF) in the animal models, but there are no clinic studies to verify this. We aimed to explore the effect of NBP on improving cerebral hypoperfusion caused by cerebral large-vessel stenosis. Methods: In this single-center, randomized, double-blind, placebo-controlled study, 120 patients with severe carotid atherosclerotic stenosis and cerebral hypoperfusion in the ipsilateral middle cerebral artery (MCA) were included and randomly assigned into the NBP or placebo group as 1:1 radio. Patients in NBP and placebo group received 200mg and 20mg of NBP capsules three times daily for four weeks respectively. Single photon emission computed tomography (SPECT) were used to assess regional CBF (rCBF) in four regions of interest (ROIs) corresponding to MCA before and 12 weeks after the treatment. The rC BF change for every ROI and the CBF change in whole MCA territory for every patient after therapy were classified into amelioration, stabilization and deterioration respectively. Results: 48 NBP patients (6 with bilateral stenosis) and 46 placebo patients (8 with bilateral stenosis) completed the trial. Both groups had 54 stenotic carotid arteries and 216 ROIs for rCBF change analysis. After therapy, the rCBF in ROIs increased in NBP group (83.5%±11.4% vs. 85.8%±12.5%, p=0.000), but had no change in placebo group (86.9%±11.6% vs. 87.8%±11.7%, p=0.331). There was higher percentages of ROIs with rCBF amelioration and stabilization in NBP group than in placebo group (93.1% vs. 79.2%, p=0.000). Ordinal regression analysis showed that NBP independently made more patients to have whole CBF amelioration in ipsilateral MCA than placebo (Wald-χ2=5.247, OR=3.31, p=0.022). Conclusions: NBP may improve the cerebral hypoperfusion in the patients with carotid artery atherosclerotic stenosis. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900028005, registered December 8th 2019- Retrospectively registered, http://www.chictr.org.cn/edit.aspx?pid=45490&htm=4.

Neurosurgery

Neurology

DL-3-n-butylphthalide

Cerebral atherosclerotic stenosis

Cerebral hypoperfusion；Cerebral blood flow

Single-Photon Emission Computed Tomography.

Hypoperfusion caused by large intracranial and extracranial atherosclerotic stenosis can impair clearance of distal emboli, which is an alternative important mechanism of ischemic stroke, in addition to thromboembolism [1-2]. Approximal 20%～30% of ischemic strokes in the United States were attributed to cerebral large-vessel stenosis[3]. The study of China National Stroke Registry Large showed that large arterial atherosclerotic stenosis accounted for 45% ischemic strokes in China [4]. In addition, many studies showed that chronic cerebral hypoperfusion was associated with a higher prevalence of cognitive impairment [5]. Therefore, improving cerebral hypoperfusion may prevent ischemic stroke and cognitive impairment. Although carotid endarterectomy (CEA) and carotid artery stenting (CAS) can normalize cerebral hemodynamics by increasing the lumen diameter and providing a better cerebral irrigation, they are not suitable to all the patients with cerebral large-vessel stenosis [6]. The augmentation of collateral vessels may also enhance the cerebral blood flow in these patients. Some pharmacologic approaches such as volume expansion, hemodilution, vasodilatation, and induced hypertension, have been suggested to increase collateral perfusion, but unfortunately, the trials of these drugs failed to demonstrate an overall clinical benefit among the participants [7]. Consequently, the American Heart Association's 2017 guidelines advised against the common use of these medicines to enhance collateral circulation [8].

Dl-3-butylphthalide (NBP) is a synthetic chiral compound based on l-3-butylphthalide, which is originally isolated from seeds of Apium graveolens [9]. The systematic review showed that the combination of NBP and standard anti-ischemic stroke agents was superior to standard drugs alone in the therapy of patients with acute ischemic stroke, based on both the Barthel index and National Institutes of Health Stroke Scale, as a neuroprotective drug [10]. The numerous animal studies also showed that NBP decreased the ischemic brain area and improved the neurological deficits. NBP could improve the cerebral microcirculation and cerebral blood flow (CBF) by vasodilatation and angiogenesis in these animal studies [11-14]. However, there are still no clinic studies to verify that NBP can improve decreased CBF in the human being.

This clinical trial was carried out to explore the effect of NBP capsules on improving cerebral hypoperfusion in the ipsilateral middle cerebral artery (MCA) territory caused by the severe carotid atherosclerotic stenosis. This study may provide an evidence-based clinical strategy to prevent ischemic stroke and vascular cognitive impairment from cerebral large-vessel stenosis and hypoperfusion.

Study design

This was a single-center, randomized, double-blind, placebo-controlled trial that enrolled 120 patients from the Air Force Medical Center PLA (People's Liberation Army) in Beijing city between January 2017 and March 2019. The trial was approved by the Institutional Review Boards in the Air Force Medical Center PLA. Participants provided written informed consent to participate in the study. This study was registered in the Chinese Clinical Trial Registry (No. ChiCTR1900028005).

Patients

The patients, who had both severe atherosclerotic stenosis in the carotid artery and cerebral hypoperfusion in the ipsilateral MCA territory, were invited to participate in this study. Eligibility criteria included the following: (1) 30-80 years of age; (2) ≥70% stenosis or occlusion in the internal carotid artery (ICA) and/or the first sphenoidal segment (M1) of MCA; (3) cerebral hypoperfusion in the ipsilateral MCA territory; (4) no transient ischemic attacks (TIA) or ischemic strokes within 2 weeks; (5) no ≥50% stenosis or occlusion in the subclavian artery, vertebral artery, basilar artery and posterior cerebral artery；(6) no or ≤15mm infarction in the territory of MCA and cerebellum on CT or MRI. We excluded the following subjects:(1) cerebral stenosis caused by other diseases than atherosclerosis, such as autoimmune disorder, vasculitis etc; (2) willing to carry out CAS or CEA; (3) contraindications for assessing cerebral stenosis and perfusion; (4) other cerebral diseases (such as infection, degeneration, demyelination etc.) which influence cerebral perfusion; (5) pregnant or lactating women; (6) severe cardiac, pulmonary, hepatic or renal diseases etc. and life expectancy ≤6 months; (7) psychotic; (8) allergy to NBP.

Randomization and drug treatment

Patients were randomly assigned in a 1:1 ratio to therapy and placebo groups. Both groups received three times daily oral NBP 200mg or 20mg (ineffective dose) for 4 weeks respectively. Patients also received optimized medical therapy (OMT) against cerebral artery atherosclerotic stenosis, including antiplatelet aggregation, lipid-lowering, antihypertension, hypoglycemia, etc. However, any vascular dilation drug was contraindicated for the patients.

An independent statistician from Chinese Beijing Medical University created the randomization list by the compute. Every kit of drug was labeled with sequential numbers corresponding to the randomization list. The successive patients were distributed with the kits from lowest number to highest number. All kits of drugs had identical appearance and similar smell. The patients and investigators were blinded to the drug allocation.

Clinical assessment and Follow-up

Initial assessments of the patients before the therapy included demographic characters, the atherosclerotic risk factors (hypertension, diabetes mellitus, hyperlipidemia, coronary heart disease and smoking), cerebral stenotic location and degree, integrity of the circle of Willis (CoW), and CBF. The medication compliance of NBP and its adverse reactions were followed up by telephone after 4 weeks. CBF was assessed again after 12 weeks. The cerebral artery stenosis and integrity of CoW were assessed by magnetic resonance angiography (MRA), computed tomography angiography (CTA), or digital subtraction angiography (DSA). The extracranial artery stenotic degree was calculated according to North American Symptomatic Carotid Endarterectomy Trial Collaborators (NASCET) and the intracranial artery stenotic degree was calculated according to Warfarin-Aspirin Symptomatic Intracranial Disease (WASID). CBF was assessed by single photon emission computed tomography (SPECT).

SPECT procedures and Region of interest (ROI) selection

SPECT brain scans were carried out in a dark and quiet environment according to our previous study [6]. 925 MBq of ethylcysteinate dimer (^99mTC-ECD, China institute of atomic energy, China) was injected into the antecubital vein. The images were taken by the SPECT scanner (Infinia Hawkeye; General Electric Company, USA) after one hour. The images were taken per 6° during rotation of 360° and at a rate of 35s per frame. The data were acquired on a 128×128 matrix.

ROI selection and data analysis were also according to previous studies [6, 15]. NeuroMatch Software package (GE Medical Systems; Segami Corporation, Columbia, MD, USA) was used for the ROI selection. Four slices of cerebral hemisphere were selected on orbitomeatal line (OML) +55mm, +58mm, +61mm, and +64mm.Six pairs of sphenoid mirrored ROIs over cortical gray matter were drawn at each slice of cerebral hemisphere. Four middle ROIs corresponding to the MCA territory were selected, and the mean value of four slices in each ROI was used for data analysis. However, mirrored ROIs were also drawn in one slice of cerebellar hemisphere (OML+15mm) for normalization of cerebral hemodynamic parameters.

Definition of CBF and cerebral hypoperfusion

The ratio of radioactive counting obtained from the ROI in the cerebral hemisphere to that from the ROI in the ipsilateral cerebellar hemisphere was calculated automatically by computer for the cerebral hemodynamic normalization, which was defined as CBF. The CBF in each ROI was called as regional CBF (rCBF). The cerebral hypoperfusion was defined as rCBF_stenosis≤90% and/or rCBF_mirror﹣rCBF_stenosis≥90% in any ROI corresponding to the ipsilateral MCA territory [15,16].

Classifications of CBF change after treatment

As for a ROI in the ipsilateral MCA of carotid artery stenosis, its rCBF change was classified according to the difference between pre-treatment and post-treatment rCBF. The rCBF amelioration was defined as rCBF_after － rCBF_before≥10%, and the rCBF deterioration was defined as rCBF_after－ rCBF_before≤-10%, and the rCBF stabilization was defined as -10%＜rCBF_after－ rCBF_before＜10% [15].

As for a patient with carotid artery stenosis, his whole CBF change in the ipsilateral MCA territory was classified according to the number of ROIs with rCBF deterioration or amelioration after treatment (4 ROIs in the unilateral stenosis and 8 ROIs in the bilateral stenosis). First, the whole CBF deterioration was defined when a patient had ≥1, ≥2, ≥3 or ≥4 ROIs with rCBF deterioration in the ipsilateral MCA territory. Correspondingly, the whole CBF amelioration was defined when a patient had ≥1, ≥2, ≥3 or ≥4 ROIs with rCBF amelioration in the ipsilateral MCA territory. At last, the whole CBF stabilization was defined in the other patients than CBF deterioration and amelioration.

Statistical analysis

Continuous variables with normal distribution were presented as mean and standard deviation (SD), and continuous variables with non-normal distribution as median and interquartile range. Categorical variables were reported as the percentage of patients in the subgroup. In univariate analysis, the Student t test or the Mann-Whitney U test was used for two class comparisons of continuous variable, and one-way ANOVA or Kruskal Wallis H test for multiple-class comparisons of continuous variables. χ² test was used for the comparisons of categorical variables. Multivariable ordinal regression models were performed with the whole CBF change after treatment as dependent variable, and NBP as independent variable. The statistical significance was defined as p≤0.05. All the resultant data were analyzed by the software of SPSS 16.0 (IBM, Amon, New York, USA).

A total of 120 patients with cerebral hypoperfusion in the ipsilateral MCA of carotid artery stenosis, participated in this study and underwent randomization. Among them, 60 were assigned to NBP group and 60 were assigned to placebo group. As shown in Figure 1, 48 patients among NBP group and 46 patients among placebo group completed treatment and follow-up. Therefore, 94 patients were included in the efficacy analysis and 26 patients (21.7%) were lost to follow up in this study. Baseline demographics and clinical characteristics were well-balanced between NBP group and placebo group, which were listed in Table 1.

rCBF outcomes for ROI analysis

Six patients had bilateral carotid artery stenosis and cerebral hypoperfusion in 48 NBP patients, and eight patients had bilateral carotid artery stenosis and cerebral hypoperfusion in 46 placebo patients. Therefore, both NBP and placebo groups had a total of 54 stenotic carotid arteries with cerebral hypoperfusion in ipsilateral MCA respectively. Since there were 4 ROIs in the MCA, both groups had 54×4=216 ROIs available for rCBF change analysis respectively. In NBP group, the rCBF in all the ROIs significantly increased after treatment (83.5%±11.4% vs. 85.8%±12.5%, p=0.000). However, there was no significant change of the rCBF in placebo group (86.9%±11.6% vs. 87.8%±11.7%, p=0.331). In NBP group, the numbers of ROIs with rCBF deterioration, stabilization and amelioration were 15(6.9%), 161(74.5%) and 40(18.5%) respectively, and in placebo group, the numbers of ROIs with rCBF deterioration, stabilization and amelioration were 45(20.8%), 126(67.6%) and 25(11.6%) respectively. There were significantly higher percentages of ROIs with rCBF amelioration and stablization in NBP group than those in placebo group ((93.1% vs. 79.2%, p=0.000, Figure 2).

Whole CBF outcomes in ipsilateral MCA for patient analysis

No matter what was defined as whole CBF outcomes (deterioration, amelioration and stablization) in the ipsilateral MCA territory, the NBP group always had higher percentages of patients with whole CBF amelioration and stabilization than placebo group (Table 2). When the whole CBF amelioration/deterioration was defined as the numbers of ROIs with rCBF amelioration/deterioration in the patients ≥1, the difference of whole CBF outcomes between two groups was not significant. On the contrary, when the whole CBF amelioration/deterioration was defined as the numbers of ROIs with rCBF amelioration/deterioration in the patients ≥2, ≥3 or ≥4, the differences of whole CBF outcomes between two groups became significant (Table 2). However, when the numbers of ROIs were defined as ≥3 and ≥4, the patients who had whole CBF amelioration/deterioration were too few to make the regression analysis. Finally, the number of ROIs ≥2 was defined as whole CBF amelioration/deterioration to analyze the regression. The ordinal regression analysis showed that after adjusted for demographics, atherosclerotic risk factors, cerebral stenotic characteristics and integrity of CoW, NBP was still an independent factor to improve and stabilize impaired CBF caused by carotid artery stenosis (Table 3). Figure 3 and Figure 4 showed the classical cases whose rCBF in the ipsilateral MCA increased in NBP group and decreased in placebo group.

Our randomized, double-blind, placebo-controlled trial showed that four weeks of orally NBP therapy improved the rCBF in the ipsilateral MCA of carotid artery stenosis. There were higher percentages of ROIs with rCBF amelioration and stablization after treatment in NBP group than in placebo group. Compared with placebo group, NBP group had more than two times of patients who had the whole CBF amelioration in the ipsilateral MCA.

BNP was licensed as a novel drug for clinical trials in 2002. Based on the results from the multicenter phase 2 and 3 randomized controlled clinical trials, which consistently reported that 21-day or 90-day orally or intravenously NBP therapy could improve neurological deficits and activity of daily life (ADL) scoring after acute ischemic stroke, with a good safety and tolerability, NBP was approved as a therapeutic drug for ischemic stroke by the State Food and Drug Administration of China (SFDA) in 2005 [9, 10]. Therefore, NBP was recommended to treat the acute ischemic stroke by Chinese Guidelines for the Management of Stroke since 2010[17]. A multicentre, randomized, double-blind, placebo-controlled trial recently showed that a 6-month NBP treatment was also effective for improving cognitive and global functioning in the patients with subcortical vascular cognitive impairment no dementia (VCIND) [18]. Another retrospective case-control study showed that postoperative administration of 7-day NBP injection was able to alleviate perioperative neurological deficits after revascularization surgery for the patients with moyamoya disease [19]. NBP might play the positive effects on these diseases through the mechanism of improving the cerebral hypoperfusion [9,10], since it had been demonstrated that the ischemic stroke, vascular cognitive impairment and perioperative neurological deficits of moyamoya disease after revascularization surgery were partially attributed to acute, chronic or fluctuating cerebral hypoperfusion[1,5,19]. An animal study had showed that NBP increased cerebral microvessels and perfusion, and decreased the volume of the cerebral infarct in the rats of cold-induced ischemic stroke [14]. NBP also accelerated CBF in the chronic cerebral hypoperfusion (CCH) rats after permanent bilateral common carotid artery occlusion, and prevented CCH-induced white matter damage and cognitive impairment [11, 13]. In addition, NBP was found to improve rCBF in the caudate nucleus for the rats subjected to subarachnoid hemorrhage [20]. By contrast, high-quality clinical trial was lack to demonstrate that NBP increased CBF and improved cerebral hypoperfusion.

Our study firstly demonstrated that NBP could improve the cerebral hypoperfusion in the patients with carotid artery atherosclerotic stenosis. However, some important points must be noted to explain and apply this result. First, all the patients in this study had decreased CBF before the treatment because of severe carotid artery stenosis and poor collateral circulation, which suggested that the hemodynamic impairement existed distal to cerebral artery stentosis. In addition, our study excluded the patients who had acute ischemic cerebral vascular diseases before the trial, which suggested that the patients included in this study had chronic cerebral hypoperfusion. Therefore, this trial provided the new therapy method for the patients with CCH resulted from the carotid artery stenosis [1, 5, 19]. Second, NBP was used with the combination of OMT against atherosclerotic ischemic stroke in this study, because these patients had the large intracranial or extracranial stenosis. Therefore, the effect of NBP on improving CCH in the patients with the cerebral artery stenosis must base on the anti-arthrosclerosis OMT, but not NBP alone [21]. Third, NBP was orally taken for 4 weeks in our study, but the CBF examination after treatment was carried out 12 weeks after the trial beginning in consideration of the radioactivity of the SPECT test. Therefore, this positive result suggested that NBP had a persistent effect on improving the cerebral hypoperfusion in the patients with the cerebral artery stenosis.

The collateral circulation of the brain may be defined as the artery-to-artery anastomotic pathways that are capable, when needed, of supplying nutrient perfusion to a brain region whose primary source of blood flow has been reduced or compromised by disease [22]. In humans, it is generally recognized that there are three pathways of cerebral collaterals. The brain’s primary collateral pathway consists of the CoW－the anastomotic array of arteries at the base of the brain that connect the anterior and posterior portions of the cerebral circulation. The brain’s secondary collateral pathways can be accessed through the ophthalmic artery and leptomeningeal vessels when collateral flow through the CoW is inadequate. The additional collateral pathway also includes the neovascularization [22, 23]. One clinic study showed that NBP injection increased much more brain’s primary and secondary collaterals than the control injection in the patients of acute ischemic stroke [24]. The animal studies demonstrated that NBP promoted the new angiogenesis in the rats of acute ischemic stroke or CCH [11, 12, 25]. Therefore, these results supported the opinion that NBP could improve the cerebral hypoperfusion in the patients with cerebral artery stenosis by increasing the brain’s collateral circulation. The mechanisms that NBP increases the brain’s collateral circulation may be as follows. First, nitric oxide (NO) released from vascular endothelium was thought to participate in arteriogenesis and vasodilation and increase the cerebral collateral. NBP significantly increased the activity of NOS and production of extracellular NO in bovine aortic endothelial cells and bovine cerebral endothelial cells, which might improve the cerebral microcirculation and restore the supply of oxygen and nutrients to ischemic hemisphere [9, 22]. Second, NBP also promote the angiogenesis or revascularization by up-regulating the expressions of various angiogenic factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and transforming growth factor-β1 (TGF-β1) [12,25-27], or by regulating some signaling axes or pathways [28, 29].

Since NBP smelled plant odor, the placebo medicine was designed as a low and ineffective dose (10 mg NBP per pill) rather than a blank one, in order to make sure of an effective double-blind in this trial. However, there were also some limitations in this study. First, this study was a single-center trial, and had a relatively small sample size and a little high lost follow-up rate. Therefore, a multiple-centers and large sample size of trial needs to verify the results in this study. Second, some patients in this study completed the CBF examination more than 12 weeks after treatment, but there was not a significant difference in the follow-up time between NBP group and placebo group. Therefore, the results in this study may not be affected by this follow-up prolongation.

Our trial showed that on the basis of OMT，NBP improved the cerebral hypoperfusion in the patients with carotid artery atherosclerotic stenosis. This study provides a new therapy strategy to prevent ischemic stroke and vascular cognitive impairment due to cerebral large-vessel stenosis and hypoperfusion.

CEA: carotid endarterectomy; CAS: carotid artery stenting; NBP: Dl-3-butylphthalide; CBF: cerebral blood flow; MCA: middle cerebral artery; PLA: People's Liberation Army; ICA: internal carotid artery; TIA: transient ischemic attacks; OMT: optimized medical therapy; CoW: circle of Willis; MRA: magnetic resonance angiography; CTA: computed tomography angiography; DSA: digital subtraction angiography; NASCET: North American Symptomatic Carotid Endarterectomy Trial Collaborators; WASID: Warfarin-Aspirin Symptomatic Intracranial Disease; SPECT: single photon emission computed tomography; ROI: Region of interest; ECD: ethylcysteinate dimer; OML: orbitomeatal line; ADL: activity of daily life; SFDA: State Food and Drug Administration; VCIND: subcortical vascular cognitive impairment no dementia; CCH: chronic cerebral hypoperfusion; NO: nitric oxide; VEGF: vascular endothelial growth factor; bFGF: basic fibroblast growth factor; TGF-β1:transforming growth factor-β1

Acknowledgments:

The therapy and placebo medications of DL-3-n-butylphthalide were donated by the Shijiazhuang Pharmaceutical Group Co that had no other role in this study.

Author Contributions:

DC has made substantial contributions to design and has been involved in drafting of the manuscript. JS has made substantial contributions to the design and given final approval of the version to be submitted. YY has made substantial contributions to design and revised the manuscript. FY has made substantial contributions to statistical analysis. KW has contributed greatly in data collection and management. FZ has contributed to the patients’ follow-up. WL has revised the manuscript. BL has contributed to SPECT technique. All authors read and approved the final manuscript.

Funding

This work was funded by Ministry of Sciences and Technology of Air Force Medical Center, PLA (No. 2014ZX09104002-002). The funder provided support for the study to be carried out and published, but not any other role during the execution of the study, analyses, interpretation of the data, or decision to submit results.

Availability of data and materials

The data can be accessed through http://www.medresman.org.cn/uc/project/projectedit.aspx?proj=5952.

Statement of Ethics

Written informed consent was obtained from all study participants or their legal representatives. The protocol for this trial was approved by the Institutional Review Boards in the Air Force Medical Center, PLA, China.

Consent for publication

Not applicable.

Competing interests

All the authors have no conflict of interest.

Other statement

My study and manuscript reporting adhered to CONSORT (Consolidated Standards of Reporting Trials) guidelines.

1 Banerjee C, Turan TN. Large Artery Atherosclerosis: Extracranial and Intracranial. Semin Neurol. 2017 Jun; 37(3):307-15. DOI: 10.1055/s-0037-1603588.

2 Shakur SF, Hrbac T, Alaraj A, Du X, Aletich VA, Charbel FT, et al. Effects of extracranial carotid stenosis on intracranial blood flow. Stroke. 2014 Nov; 45(11): 3427-9. DOI: 10.1161/STROKEAHA.114.006622.

3 Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics—2016 Update: A report from the American Heart Association. Circulation. 2016 Jan; 133(4):e38–360. DOI: 10.1161/CIR.0000000000000350.

4 Xu J，Liu L，Wang Y，Zhao X, Wang C, Wang A, et al. TOAST subtypes：its influence upon doctors' decisions of antihypertensive prescription at discharge for ischemic stroke patients. Patient Prefer Adherence, 2012, 6:911-4. DOI: 10.2147/PPA.S38565.

5 Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor's Choice - Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018 Jan; 55(1):3-81. DOI: 10.1016/j.ejvs.2017.06.021.

6 Chen DW, Zheng J, Shi J, Yin YW, Song C, Yang F, et al..Assessment of the Cerebral Hemodynamic Benefits of Carotid Artery Stenting for Patients with Preoperative Hemodynamic Impairment Using Cerebral Single Photon Emission Computed Tomography (SPECT) and Carbon Dioxide Inhalation. Med Sci Monit. 2018 Aug; 24:5398-5404. DOI: 10.12659/MSM.909401.

7 Nishijima Y, Akamatsu Y, Weinstein PR, Liu J. Collaterals: Implications in cerebral ischemic diseases and therapeutic interventions. Brain Res. 2015 Oct; 1623:18-29. DOI: 10.1016/j.brainres.2015.03.006.

8 Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar; 49(3):e46-e110. DOI: 10.1161/STR.0000000000000158.

9 Wang S, Ma F, Huang L, Zhang Y, Peng Y, Xing C, et al. Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke. CNS Neurol Disord Drug Targets. 2018, 17(5):338-47. DOI: 10.2174/1871527317666180612125843.

10 Xu ZQ, Zhou Y, Shao BZ, Zhang JJ, Liu C. A Systematic Review of Neuroprotective Efficacy and Safety of DL-3-N-Butylphthalide in Ischemic Stroke. Am J Chin Med. 2019 Apr; 47(3):507-25. DOI: 10.1142/S0192415X19500265.

11 Xiong Z, Lu W, Zhu L, Zeng L, Shi C, Jing Z, et al. Dl-3-n-Butylphthalide Treatment Enhances Hemodynamics and Ameliorates Memory Deficits in Rats with Chronic Cerebral Hypoperfusion. Front Aging Neurosci. 2017 Jul; 9:238. DOI: 10.3389/fnagi.2017.00238.

12 Zhang L, Lü L, Chan WM, Huang Y, Wai MS, Yew DT. Effects of DL-3-n-butylphthalide on vascular dementia and angiogenesis. Neurochem Res. 2012 May; 37(5):911-9. DOI: 10.1007/s11064-011-0663-3.

13 Han QY, Zhang H, Zhang X, He DS, Wang SW, Cao X, et al. dl-3-n-butylphthalide preserves white matter integrity and alleviates cognitive impairment in mice with chronic cerebral hypoperfusion. CNS Neurosci Ther. 2019 Sep; 25(9):1042-53. DOI: 10.1111/cns.13189.

14 Liu CL, Liao SJ, Zeng JS, Lin JW, Li CX, Xie LC, et al. dl-3n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP. J Neurol Sci. 2007 Sep; 260(1-2):106-13.DOI:10.1016/j.jns.2007.04.025.

15 Kim HJ, Kim TW, Ryu SY, Yang PS, Kwon MJ, Kim JC, et al. Acetazolamide-challenged perfusion magnetic resonance imaging for assessment of cerebrovascular reserve capacity in patients with symptomatic middle cerebral artery stenosis: comparison with technetium-⁹⁹m-hexamethylpropyleneamine oxime single-photon emission computed tomography. Clin Imaging. 2011 Nov-Dec; 35(6):413-20. DOI: 10.1016/j.clinimag.2011.03.001.

16 Abe A, Ueda T, Ueda M, Nogoshi S, Nishiyama Y, Katayama Y. Symptomatic middle cerebral artery stenosis treated by percutaneous transluminal angioplasty: improvement of cerebrovascular reserves. Interv Neuroradiol. 2012 Jun; 18(2):213-20. DOI:10.1177/159101991201800215.

17 Cerebraovascular Disease Working Groups. Chinese guidelines for the management of acute ischemic stroke. Chin.J.Neurol. 2010 Feb; 43(2):146-53. DOI:10.3760/ema.j.issn.1006-7876.2010.02022.

18 Jia J, Wei C, Liang J, Zhou A, Zuo X, Song H, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial. Alzheimers Dement. 2016 Feb; 12(2):89-99. DOI: 10.1016/j.jalz.2015.04.010.

19 Li Z, Lu J, Ma L, Wu C, Xu Z, Chen X, et al. dl-3-n-butylphthalide for alleviation of neurological deficit after combined extracranial-intracranial revascularization for moyamoya disease: a propensity score-matched analysis. J Neurosurg. 2019 Feb; 15:1-13. DOI: 10.3171/2018.10. JNS182152.

20 Chong ZZ, Feng YP. dl-3-n-butylphthalide improves regional cerebral blood flow after experimental subarachnoid hemorrhage in rats. Zhongguo Yao Li Xue Bao. 1999 Jun; 20(6):509-12.

21 Spence JD, Naylor AR. Endarterectomy, Stenting, or Neither for Asymptomatic Carotid-Artery Stenosis. N Engl J Med. 2016 Mar; 374(11):1087-8. DOI: 10.1056/NEJMe1600123.

22 Ginsberg MD. The cerebral collateral circulation: Relevance to pathophysiology and treatment of stroke.Neuropharmacology. 2018 May; 134(Pt B):280-92. DOI: 10.1016/j.neuropharm.2017.08.003.

23 Liu J, Wang Y, Akamatsu Y, Lee CC, Stetler RA, Lawton MT, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog Neurobiol. 2014 Apr; 115:138-56. DOI: 10.1016/j.pneurobio.2013.11.004.

24 Wu Yu-Fu, Liu Xiao-Hong, Guo Wei-Cheng, Zhao Jie, Wang Hao-Ran, He Fei-Fei. Effect. Observation of Butylphthalide Injection in Treating Acute Anterior Circulation Infarction. Chin J Stroke. 2017 Dec; 12(12):1111-4. DOI: 10.3969/j.issn.1673-5765.2017.12.008

25 Liao SJ, Lin JW, Pei Z, Liu CL, Zeng JS, Huang RX. Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP. Brain Res. 2009 Sep; 1289:69-78. DOI: 10.1016/j.brainres.2009.06.018.

26 Zhou PT, Wang LP, Qu MJ, Shen H, Zheng HR, Deng LD, et al. Dl-3-N-butylphthalide promotes angiogenesis and upregulates sonic hedgehog expression after cerebral ischemia in rats. CNS Neurosci Ther. 2019 Jun; 25(6):748-58. DOI:10.1111/cns.13104.

27 Jiang Y, Sun L, Xuan X, Wang J. Impacts of N-Butylphthalide on expression of growth factors in rats with focal cerebral ischemia. Bosn J Basic Med Sci. 2016 Jan, 16(2):102-7. DOI: 10.17305/bjbms.2016.560.

28 Li W, Wei D, Xie X, Liang J, Song K, Huang L. Dl-3-n-Butylphthalide regulates the Ang-1/Ang-2/Tie-2 signaling axis to promote neovascularization in chronic cerebral hypoperfusion. Biomed Pharmacother. 2019 May; 113:108757. DOI: 10.1016/j.biopha.2019.108757.

29 Lu XL, Luo D, Yao XL, Wang GL, Liu ZY, Li ZX, et al. dl-3n-Butylphthalide promotes angiogenesis via the extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase/Akt-endothelial nitric oxide synthase signaling pathways. J Cardiovasc Pharmacol. 2012 Apr; 59(4):352-62. DOI: 10.1097/ FJC.0b013e3182443e74.

Table 1. Baseline characteristics of 94 patients for the efficacy analyses

Characteristics	NBP group(n=48)	Control group(n=46)	P values
Age (years)	56.6±11.5	60.6±10.3	0.085
Gender (male)	39（81.2%）	32（69.6%）	0.188
Hypertention(yes)	38（79.2%）	39（84.8%）	0.479
Diabetes mellitus(yes)	19(39.6%)	22(47.8%)	0.420
Hyperlipemia(yes)	37(77.1%)	38(82.6%)	0.505
Coronary disease(yes)	8(16.7%)	12(26.1%)	0.265
Smoking(yes)	29（60.4%）	24（52.2%）	0.420
Methords for assessing stenosis
MRA	35（72.9%）	30(65.2%)	0.316
CTA	1（2.1%）	0(0%)
DSA	12（25.0%）	16(34.8%)
Unilateral or bilateral
Right side	20（41.7%）	22（47.8%）	0.526
Left side	22（45.8%）	16（34.8%）
Bilateral	6（12.5%）	8（17.4%）
Stenotic location
Extracranial ICA	10（20.8%）	8（17.4%）	0.118
Intracranial ICA	23（47.9%）	31（67.4%）
MCA(M1 segment)	15（31.2%）	7（15.2%）
Stenotic severity
Severe stenosis（70-99%）	35（72.9%）	40（87.0%）	0.090
Occlusion	13（27.1%）	6（13.0%）	0.090
Integrity of CoW
Integrity	11（22.9%）	17（37.0%）	0.137
Unintegrity	37（77.1%）	29（63.0%）	0.137
Time of follow-up (month)	3.7±1.6	3.5±0.9	0.516

NBP=Dl-3-butylphthalide; MRA=magnetic resonance angiography; CTA= computed tomography angiography; DSA= digital subtraction angiography; ICA= internal carotid artery; MCA=middle cerebral artery; CoW=circle of Willis.

Table 2. Comparisons of whole CBF outcomes in ipsilateral MCA territory of carotid artery system stenosis between NBP group and placebo group

Number of ROIs with rCBF amelioration/deterioration	Group	Deterioration n (%)	Stablization n (%)	Amelioration n (%)	χ2	P values
≥1	NBP	10（20.8%）	23（47.9%）	15（31.2%）	2.049	0.359
≥1	Control	15（32.6%）	21（45.7%）	10（21.7%）	2.049	0.359
≥2	NBP	1（2.1%）	37（77.1%）	10（20.8%）	11.362	0.003
≥2	Control	12（26.1%）	27（58.7%）	7（15.2%）	11.362	0.003
≥3	NBP	1（2.1%）	40（83.3%）	7（14.6%）	8.799	0.012
≥3	Control	10（21.7%）	31（67.4%）	5（10.9%）	8.799	0.012
≥4	NBP	0（0.0%）	43（89.6%）	5（10.4%）	6.441	0.015
≥4	Control	5（10.9%）	39（84.8%）	2（4.3%）	6.441	0.015

Definitions of CBF outcomes were according to the number of ROIs with rCBF amelioration/deterioration. CBF=cerebral blood flow; MCA=middle cerebral artery; NBP Dl-3-butylphthalide; ROI= regions of interest; rCBF=regional CBF.

Table 3. Odds ratios of NBP vs. placebo for whole CBF outcomes in ipsilateral MCA territory of carotid artery system stenosis.

Adjusted factors	Wald-χ²	P values	OR(95%CI)
None	6.080	0.014	3.23（1.02-8.19）
Demographics and artherosclerotic risk factors	5.687	0.017	3.38（1.24-9.19）
Demographics, artherosclerotic risk factors, cerebral stenotic characteristics and integrity of CoW	5.247	0.022	3.31（1.19-9.20）

NBP Dl-3-butylphthalide; CBF=cerebral blood flow; MCA=middle cerebral artery; CoW=circle of Willis. Demographics included age and sex; Artherosclerotic risk factors included hypertention, diabetes mellitus, hyperlipemia, coronary disease and smoking; Cerebral stenotic characteristics included stenotic location and degree.

CONSORTchecklist.pdf

DL-3-n-butylphthalide improves cerebral hypoperfusion in patients with large cerebral artherosclerotic stenosis. A single-center, randomized, double-blind, placebo-controlled study.

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Methods

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Tables

Supplementary Files

Status:

Journal Publication

Version 1